BioCentury
ARTICLE | Company News

Retrophin, Sanofi gastrointestinal news

June 1, 2015 7:00 AM UTC

Retrophin sold its rare pediatric disease Priority Review voucher to Sanofi for $245 million. Retrophin will receive $150 million up front, plus $47.5 million in 2016 and $47.5 million in 2017. Retrophin gained the voucher through its acquisition of Cholbam cholic acid from Asklepion Pharmaceuticals LLC (Baltimore, Md.) earlier this year. Asklepion received the voucher in March when FDA approved the cholic acid capsules to treat bile acid synthesis disorders due to single enzyme defects in pediatric and adult patients and as an adjuvant to treat peroxisomal disorders, including Zellweger spectrum disorders (see BioCentury, March 23). ...